Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 3/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.40 |
| ▸ | LPAR5 | Q9H1C0 | 6/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3375868 | 0.84 | PTGER4 (0.46) | PTGER4PTGER2KMT2ATSHR | |
| SCHEMBL14732164 | 0.80 | LPAR1 (0.49) | FEN1LPAR1LPAR5 | |
| SCHEMBL3378385 | 0.78 | FABP4 (0.48) | PTGER4FABP4LPAR1LPAR5TSHR | |
| SCHEMBL3378390 | 0.78 | FFAR4 (0.43) | FFAR1KMT2ATSHR | |
| SCHEMBL3376139 | 0.77 | KMT2A (0.47) | KMT2ATSHR | |
| SCHEMBL3380135 | 0.76 | SRD5A2 (0.57) | KMT2ATSHR | |
| SCHEMBL3376158 | 0.73 | SCN9A (0.39) | KMT2A | |
| SCHEMBL3378922 | 0.68 | KIF11 (0.56) | PTGER4KMT2A | |
| SCHEMBL3130872 | 0.68 | TTR (0.68) | LPAR1LPAR5 | |
| SCHEMBL5156190 | 0.67 | LMNA (0.68) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389500-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2013-03-05 | — | — | US | claimed |
| WO-2010056527-A2 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-20 | — | — | WO | claimed |
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | claimed |
| WO-2010056527-A2 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNH2 | FEN1 4857/4885PTGER4 508/4885FABP4 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.